Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Clinical heterogeneity of LRRK2 p.I2012T mutation.

Fan TS, Wu RM, Chen PL, Chen TF, Li HY, Lin YH, Chen CY, Chen ML, Tai CH, Lin HI, Lin CH.

Parkinsonism Relat Disord. 2016 Dec;33:36-43. doi: 10.1016/j.parkreldis.2016.09.008. Epub 2016 Sep 7.

PMID:
27628070
2.

Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.

Hatano T, Funayama M, Kubo S, Mata IF, Oji Y, Mori A, Zabetian CP, Waldherr SM, Yoshino H, Oyama G, Shimo Y, Fujimoto K, Oshima H, Kunii Y, Yabe H, Mizuno Y, Hattori N.

Neurobiol Aging. 2014 Nov;35(11):2656.e17-23. doi: 10.1016/j.neurobiolaging.2014.05.025. Epub 2014 Jun 2.

3.

Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Rudenko IN, Cookson MR.

Neurotherapeutics. 2014 Oct;11(4):738-50. doi: 10.1007/s13311-014-0284-z. Review.

4.

Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.

Wang C, Cai Y, Gu Z, Ma J, Zheng Z, Tang BS, Xu Y, Zhou Y, Feng T, Wang T, Chen SD, Chan P; Chinese Parkinson Study Group..

Neurobiol Aging. 2014 Mar;35(3):725.e1-6. doi: 10.1016/j.neurobiolaging.2013.08.012. Epub 2013 Oct 3.

PMID:
24095219
5.

Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation.

Angeli A, Mencacci NE, Duran R, Aviles-Olmos I, Kefalopoulou Z, Candelario J, Rusbridge S, Foley J, Pradhan P, Jahanshahi M, Zrinzo L, Hariz M, Wood NW, Hardy J, Limousin P, Foltynie T.

Mov Disord. 2013 Sep;28(10):1370-5. doi: 10.1002/mds.25535. Epub 2013 Jul 1.

6.

The neuropathology of genetic Parkinson's disease.

Poulopoulos M, Levy OA, Alcalay RN.

Mov Disord. 2012 Jun;27(7):831-42. doi: 10.1002/mds.24962. Epub 2012 Mar 26. Review.

7.

A Korean Parkinson's disease family with the LRRK2 p.Tyr1699Cys mutation showing clinical heterogeneity.

Kim JS, Cho JW, Shin H, Lee WY, Ki CS, Cho AR, Kim HT.

Mov Disord. 2012 Feb;27(2):320-4. doi: 10.1002/mds.24033. Epub 2011 Dec 9.

PMID:
22162019
8.

Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation.

Wider C, Dickson DW, Wszolek ZK.

Neurodegener Dis. 2010;7(1-3):175-9. doi: 10.1159/000289232. Epub 2010 Mar 3.

9.

The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy.

Cho JW, Kim SY, Park SS, Jeon BS.

J Clin Neurol. 2009 Mar;5(1):29-32. doi: 10.3988/jcn.2009.5.1.29. Epub 2009 Mar 31.

10.

Genetic factors influencing age at onset in LRRK2-linked Parkinson disease.

Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J.

Parkinsonism Relat Disord. 2009 Aug;15(7):539-41. doi: 10.1016/j.parkreldis.2008.10.008. Epub 2008 Nov 28.

PMID:
19041274
11.

Clinical heterogeneity of the LRRK2 G2019S mutation.

Papapetropoulos S, Singer C, Ross OA, Toft M, Johnson JL, Farrer MJ, Mash DC.

Arch Neurol. 2006 Sep;63(9):1242-6.

PMID:
16966501
12.

Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.

Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA.

J Neurol Neurosurg Psychiatry. 2006 May;77(5):665-7.

13.

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ.

Brain. 2005 Dec;128(Pt 12):2777-85. Epub 2005 Aug 4.

PMID:
16081470

Supplemental Content

Loading ...
Support Center